Skip to main content
. Author manuscript; available in PMC: 2013 Jun 1.
Published in final edited form as: Matrix Biol. 2012 Apr 16;31(5):299–307. doi: 10.1016/j.matbio.2012.03.002

Figure 5. Osteonectin-null bone matrices promote prostate cancer cell proliferation.

Figure 5

(A) PC-3 cells were grown on wild type or osteonectin-null matrices, and pulsed with 3H-thymidine on the indicated days. (B) PC-3 cells were grown on osteonectin-null matrices, in the presence or absence of 3 µg/mL recombinant human osteonectin, then pulsed with 3H-thymidine on the indicated days. (C) PC-3 cells (PC) or MG-63 (MG) cells were grown to confluence. Osteonectin in serum-free conditioned medium was analyzed by Western blot analysis. Molecular weight standards (kDa) are indicated on the left of the panel. (D) Serum-deprived cultures of PC-3 cells were treated for 24 hours with conditioned medium from PC-3 cells that had been cultured for 7 days on wild type or osteonectin-null matrices. Cells were then pulsed with 3H-thymidine. Dilutions of medium tested: 100% conditioned medium, 1:2 and 1:3 dilution of conditioned medium in 10% FBS. * = significantly different from WT, p<0.05.